Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among Patients with Early-Stage TNBC By Ogkologos - November 8, 2024 520 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-522 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Cancer “Decoys” Planted Underneath The Skin Lure In Cancer Cells And... November 4, 2019 Some Children with Liver Cancer May Need Less Chemotherapy, Study Suggests May 9, 2019 FDA Approves Elacestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... February 7, 2023 New Device Could “Hear” Stiffening of Extracellular Matrix to Determine Where... April 2, 2020 Load more HOT NEWS Immunotherapy’s Role in Treating Endometrial Cancer Expected to Grow 2021/22 in review: Charity looks to the future with ambitious new... NRG1 Fusion–positive Lung Cancers are Molecularly, Pathologically, and Clinically More Heterogeneous... FDA Approves Fruquintinib for Patients with Refractory Metastatic Colorectal Cancer
